Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341904 | 0.71 | KDM4E (0.47) | MAOBSMN1; SMN2MAPTATMGAA | |
| SCHEMBL134931 | 0.71 | CYP1A2 (0.34) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL4901695 | 0.71 | TDP2 (0.34) | MAPTTDP2NSD2ABL1PLCG1 | |
| SCHEMBL10998090 | 0.70 | LMNA (0.36) | MAOBSMN1; SMN2MAPTATMHPGD | |
| SCHEMBL3515455 | 0.70 | MAOB (0.38) | MAOBSMN1; SMN2MAPTATMHPGD | |
| SCHEMBL223857 | 0.70 | CA12 (0.33) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL626927 | 0.69 | MIF (0.35) | MAPK14TDP2NSD2ABL1PLCG1 | |
| SCHEMBL4507981 | 0.69 | MAOB (0.43) | MAOBSMN1; SMN2MAPTATMHPGD | |
| SCHEMBL29606008 | 0.69 | MAOB (0.43) | MAOBSMN1; SMN2MAPTATMHPGD | |
| Hydrochloric Acid SCHEMBL4501139 | 0.68 | MAOB (0.42) | MAOBSMN1; SMN2MAPTATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-RE47396-E1 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190111016-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180265503-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7491714-B2 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-02-17 | — | — | US | disclosed |
| EP-1567520-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| EP-1567520-A4 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-06-01 | — | — | US | disclosed |
| EP-1567520-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050036-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOB 2010/4885SMN1; SMN2 2967/4885MAPT 4314/4885 |
| US-20180265503-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOB 2579/4885SMN1; SMN2 2763/4885MAPT 4198/4885 |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOB 2579/4885SMN1; SMN2 2763/4885MAPT 4198/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOB 2579/4885SMN1; SMN2 2763/4885MAPT 4198/4885 |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOB 3492/4885SMN1; SMN2 2766/4885MAPT 3810/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | MAOB 2010/4885SMN1; SMN2 2967/4885MAPT 4314/4885 |
| US-20190111016-A1 | METHODS OF TREATING MUSCLE AND LIVER DISORDERS | CKMT1A; CKMT1B, CPT1B, GLS2 | MAOB 1261/4885SMN1; SMN2 342/4885MAPT 2856/4885 |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | MAOB 2010/4885SMN1; SMN2 2967/4885MAPT 4314/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | MAOB 2579/4885SMN1; SMN2 2763/4885MAPT 4198/4885 |
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MAOB 551/4885SMN1; SMN2 2854/4885MAPT 4528/4885 |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | NQO2, NQO1, NPM1 | MAOB 1395/4885SMN1; SMN2 3234/4885MAPT 2861/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MAOB 2010/4885SMN1; SMN2 2967/4885MAPT 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.